FindTrial
Sign In

BXQ-350

DRUG5 trials

Sponsors

Bexion Pharmaceuticals, Inc.

Conditions

Chemotherapy-induced Peripheral NeuropathyMetastatic Colorectal CarcinomaNeoplasmsNeuropathyNeuropathy;Peripheral

Early Phase 1

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients
CompletedNCT05291286
Bexion Pharmaceuticals, Inc.Chemotherapy-induced Peripheral Neuropathy, Neuropathy;Peripheral
Start: 2022-10-17End: 2024-12-20Updated: 2025-01-27

Phase 1

Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors
CompletedNCT02859857
Bexion Pharmaceuticals, Inc.Neoplasms
Start: 2016-09-01End: 2020-06-15Updated: 2021-07-22
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
TerminatedNCT03967093
Bexion Pharmaceuticals, Inc.Neoplasms
Start: 2019-04-15End: 2020-01-17Updated: 2021-07-22
Continued Treatment for Participants Enrolled in Studies of BXQ-350
TerminatedNCT04404569
Bexion Pharmaceuticals, Inc.Neoplasms
Start: 2020-06-08End: 2024-09-23Updated: 2024-12-20
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
Active, not recruitingNCT05322590
Bexion Pharmaceuticals, Inc.Metastatic Colorectal Carcinoma, Neuropathy
Start: 2023-01-09End: 2029-04-30Target: 195Updated: 2024-12-20

Related Papers

BXQ-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN and neutropenia—A phase 1b/2a trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.
Journal of Clinical Oncology2026-05-27
Abstract CT084: A Phase 1b/2a study to evaluate the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma patients (mCRC): Evidence of lower incidence and severity of CIPN events
Cancer Research2026-04-17
Abstract CT220: A Phase 1b/2a study to evaluate the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma patients (mCRC): Interim efficacy subset analyses
Cancer Research2026-04-17
Abstract 3737: BXQ-350: A novel biologic that targets dysregulated sphingolipid metabolism and normalizes key anti-tumoral and pro-tumoral sphingolipids in newly diagnosed metastatic colorectal carcinoma patients (mCRC)
Cancer Research2026-04-03
Abstract 3616: BXQ-350 reduces incidence, severity, and time to on-set of chemotherapy induced peripheral neuropathy via modulation of sphingolipid metabolism
Cancer Research2026-04-03
Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.
Journal of Clinical Oncology2026-01-10
A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma.
Journal of Clinical Oncology2026-01-10
BXQ-350 efficacy and safety evaluation in first line mCRC patients: A phase 1b/2 study of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 plus bevacizumab in newly diagnosed metastatic colorectal carcinoma.
Journal of Clinical Oncology2026-01-10
BXQ-350, a novel sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal cancer (mCRC) patients: A phase 1b/2 randomized study.
Journal of Clinical Oncology2025-01-27
Abstract 3072: BXQ-350: A novel biologic that allosterically activates glucosylcerebrosidase and demonstrates signs of activity in cancer patients
Cancer Research2024-03-221 citations
BXQ-350: A phase 1b/2 placebo controlled, double blinded study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma (mCRC).
Journal of Clinical Oncology2024-01-203 citations
TRLS-06. A PHASE 1, SAFETY AND DOSE ESCALATION STUDY OF BXQ-350 IN COMBINATION WITH RADIATION IN PEDIATRIC PATIENTS WITH DIFFUSE MIDLINE GLIOMA OR DIFFUSE INTRINSIC PONTINE GLIOMA
Neuro-Oncology2023-06-011 citations
Abstract 3042: BXQ-350 may protect peripheral nerves from the direct cytotoxicity of chemotherapeutic agents leading to chemotherapy induced peripheral neuropathy
Cancer Research2023-04-04
BXQ-350 may alleviate symptoms of chemotherapy- induced peripheral neuropathy via modulation of S1P.
Journal of Clinical Oncology2023-02-01
BXQ-350: Modulating ceramide and sphingosine-1-phosphate for antitumor activity in patients with advanced CRC.
Journal of Clinical Oncology2023-02-01
P11.03.B BXQ-350: Modulating ceramide and Sphingosine-1-Phosphate for anti-tumor activity and potential mitigation of chemotherapy induced peripheral neuropathy
Neuro-Oncology2022-09-01
S1P/ceramides and cytokines as potential biomarkers of response following administration of bxq-350.
Journal of Clinical Oncology2022-06-011 citations
DIPG-30. A Phase 1, Safety and Dose Escalation Study of BXQ-350 in Combination with Radiation in Pediatric Patients with Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Neuro-Oncology2022-06-01
EPEN-14. A Phase 1, Safety and Dose Escalation Study of BXQ-350 in Patients with Advanced Solid Malignancies Demonstrates that BXQ-350 is Well Tolerated and Shows Signs of Potential Clinical Activity in Ependymoma Patients
Neuro-Oncology2022-06-01
Bedside to benchtop translational development: Targeting the S1P/ceramide axis may alleviate symptoms of chemical induced peripheral neuropathy.
Journal of Clinical Oncology2022-06-01

9 more papers not shown